Pharma in Transition: Trade Pressures, Domestic Manufacturing, and First-in-Class Approvals

The pharmaceutical landscape continues to evolve rapidly, shaped by geopolitical pressures, regulatory initiatives, and innovative therapies reaching the market. This week, developments range from Swiss industry leaders navigating U.S. tariffs to FDA programs supporting domestic drug manufacturing and the approval of a novel therapy for chronic lung disease. Each of these events carries important implications for pharma and biotech teams seeking to anticipate change and execute effectively.

Swiss Pharma Leaders Engage Amid U.S. Tariffs – Swiss Leaders Seek Roche, Novartis Talks Amid US Tariffs

The Swiss government has initiated dialogue with major pharmaceutical companies—Roche and Novartis—to address escalating U.S. tariff pressures. Although pharmaceuticals are currently exempt from the newly imposed 39% tariffs targeting Swiss exports—such as watches and chocolate—the sector is concerned about the possibility of future levies up to 250% as part of an ongoing U.S. Section 232 national security review. Pharmaceuticals represent Switzerland’s leading export category to the U.S., valued at approximately 32.75 billion Swiss francs last year and accounting for half of all Swiss exports to the American market. The potential extension of tariffs to this sector could depress Switzerland’s GDP by over 1%.

TruView: Even though pharmaceuticals aren't yet affected, they face substantial risk—making this industry a strategic target for trade diplomacy. For commercial and market access teams, this development is a reminder that geopolitical dynamics can directly affect pricing, reimbursement, and supply reliability. Proactively monitoring trade policies, maintaining flexible pricing strategies, and diversifying supply sources will be increasingly important to protect patient access and ensure operational continuity. Teams that integrate these considerations into forecasting and launch planning can better navigate the ripple effects of global trade disruptions.

FDA Launches Program to Boost U.S. Drug Manufacturing - Healthy Returns: FDA launches program to streamline creation of new U.S. drug manufacturing sites

The FDA has launched a program to accelerate U.S.-based drug manufacturing, aiming to reduce reliance on foreign supply chains and strengthen domestic production of critical medicines. Many companies are already making strategic investments to onshore manufacturing, including facility upgrades, workforce expansion, and process modernization. The FDA’s program complements these efforts, providing regulatory support, incentives, and technical guidance to encourage localized production.

TruView: From an industry perspective, this initiative reinforces the strategic pivot toward domestic manufacturing. Companies investing in onshore capabilities anticipate improved supply reliability and shorter lead times, while demonstrating alignment with evolving U.S. policy priorities. Market access teams should integrate these developments into value messaging, highlighting supply security and patient access as part of the overall proposition to payers and health systems.

FDA Approves Brensocatib: A First-in-Class Therapy for Chronic Lung Disease - Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

Insmed’s Brensocatib has received FDA approval for non-cystic fibrosis bronchiectasis, a chronic and progressive lung condition with limited treatment options. As a first-in-class therapy, Brensocatib represents a new mechanism of action—targeting the neutrophil serine protease pathway to reduce inflammation and improve lung function. This approval underscores the growing role of precision therapies in addressing complex diseases and highlights the importance of innovation in unmet medical needs.

TruView: Commercial and market access teams should prioritize education and engagement strategies to communicate Brensocatib’s novel mechanism and clinical benefit to prescribers, payers, and patients. Launch success will depend on effectively differentiating this therapy within the treatment landscape, establishing real-world value, and supporting uptake through data-driven evidence generation. First-in-class launches like this also provide valuable lessons for managing adoption, reimbursement, and market positioning of future innovative therapies.

This week’s developments underscore the multifaceted pressures shaping pharma and biotech today—from international trade dynamics and domestic manufacturing policy to the arrival of innovative therapies addressing unmet patient needs. Teams that anticipate these shifts, integrate cross-functional insights, and adapt strategically will be best positioned to deliver value to patients, payers, and shareholders alike.

The headlines this week are more than news—they’re signals. The organizations that interpret them well and act decisively will shape the next phase of biopharma leadership. 

TruBio Consulting helps biotech and pharma teams translate market shifts into smart, strategic action.

TruView - What Matters This Week. Tru & Simple.